Last reviewed · How we verify
ST-067
At a glance
| Generic name | ST-067 |
|---|---|
| Sponsor | Simcha IL-18, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial (PHASE1)
- ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma (PHASE1, PHASE2)
- ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE1)
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ST-067 CI brief — competitive landscape report
- ST-067 updates RSS · CI watch RSS
- Simcha IL-18, Inc. portfolio CI